Status:
COMPLETED
Health Course of Patients Undergoing Per os Anti-cancer Therapy.
Lead Sponsor:
Groupe Hospitalier Mutualiste de Grenoble
Collaborating Sponsors:
Fondation de l'Avenir
Conditions:
Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
During the last few years, the medical care of oncohematologic cancers diagnosed patients was shaken by the arrival of new therapies : targeted therapies. Very efficient, these therapies use the oral ...
Eligibility Criteria
Inclusion
- Patient who treated at the Groupe Hospitalier Mutualiste for an oncohematological pathology, and for which targeted oral therapy is indicated (Tarceva, Afinitor, Sutent, Ibrance, Revlimid, Zydelig, Imbruvica)
- Patient who has given its written consent
- Patient affiliated or beneficiary of social security system
Exclusion
- ECOG performance score \< 2
- Patient already included in an interventional clinical research protocol
- Patients protected by French law from clinical research inclusion (pregnant, in labour, breastfeeding, legally protected, under judiciary or administrative liberty deprivation)
Key Trial Info
Start Date :
April 25 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 12 2020
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT03454971
Start Date
April 25 2018
End Date
May 12 2020
Last Update
July 22 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Groupe Hospitalier Mutualiste de Grenoble
Grenoble, France, 38028